Novartis: EU approves new kind of migraine drug

(CercleFinance.com) - The European Commission has approved Novartis' Aimovig, a new kind of drug to prevent migraine, the Swiss drugmaker said on Tuesday.


Aimovig has been designed specifically to block the calcitonin gene-related peptide receptor (CGRP-R), which plays a critical role in migraine.

Novartis said many patients on Aimovig in clinical trials reported a 50% or more reduction in monthly migraine days; while safety and tolerability were similar to placebo.

Migraine is the third leading cause of disability in people under 50, with an estimated cost of up to 27 billion euros per year in Europe alone.

Copyright (c) 2018 CercleFinance.com. All rights reserved.